Eugenia Biguzzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eugenia Biguzzi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Flora Peyvandi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
10 shared publications Frits R. Rosendaal
3 shared publications- Giovanna Cozzi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
3 shared publications Luciano Baronciani
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; and
3 shared publications- Maria Teresa Pagliari
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
3 shared publications - Paola Colpani
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 156 (9) , 5030
Desmopressin (DDAVP): indications and practicalities
BACKGROUND: Desmopressin (1-deamino-8-D-arginine vasopressin, or DDAVP) is available in Switzerland for the treatment of non-severe haemophilia A and von Willebrand disease. OBJECTIVE: To provide practical guidance for the use of desmopressin in patients with non-severe haemophilia A, von Willebrand disease, bleeding disorders of unknown cause and mild platelet function disorders. METHODS: Based on the available literature and clinical experience in Switzerland, the Swiss Society of Haematology’s Haemostasis Working Group and the Swiss Haemophilia Network worked together to reach a consensus on the use of desmopressin. RESULTS AND CONCLUSIONS: Desmopressin may increase and normalise factor VIII and von Willebrand factor levels in patients with non-severe haemophilia A and von Willebrand disease and can prevent or treat bleeding in patients with bleeding disorders of unknown cause and mild platelet function disorders. A desmopressin trial is recommended to verify tolerability and identify responders, as the response to the drug is not predictable based on baseline levels of factor VIII and von Willebrand factor. Previously observed side effects and current contraindications must be carefully evaluated prior to every administration.
- 1 September 2026
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 156 (9) , 5030
Open AccessDesmopressin (DDAVP): indications and practicalities
BACKGROUND: Desmopressin (1-deamino-8-D-arginine vasopressin, or DDAVP) is available in Switzerland for the treatment of non-severe haemophilia A and von Willebrand disease. OBJECTIVE: To provide practical guidance for the use of desmopressin in patients with non-severe haemophilia A, von Willebrand disease, bleeding disorders of unknown cause and mild platelet function disorders. METHODS: Based on the available literature and clinical experience in Switzerland, the Swiss Society of Haematology’s Haemostasis Working Group and the Swiss Haemophilia Network worked together to reach a consensus on the use of desmopressin. RESULTS AND CONCLUSIONS: Desmopressin may increase and normalise factor VIII and von Willebrand factor levels in patients with non-severe haemophilia A and von Willebrand disease and can prevent or treat bleeding in patients with bleeding disorders of unknown cause and mild platelet function disorders. A desmopressin trial is recommended to verify tolerability and identify responders, as the response to the drug is not predictable based on baseline levels of factor VIII and von Willebrand factor. Previously observed side effects and current contraindications must be carefully evaluated prior to every administration.
- Open Access
- 13 February 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (2)
Recurrent venous thromboembolism: association with thrombin generation and d-dimer
- 13 February 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (2)
Open AccessRecurrent venous thromboembolism: association with thrombin generation and d-dimer
- Open Access
- 25 August 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (6) , 102174
Reply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”
- 25 August 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (6) , 102174
Open AccessReply to “Comment on: A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays”
- Open Access
- 30 March 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (3) , 100139
A comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays
- 30 March 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (3) , 100139
Open AccessA comparative study in patients with type 2 von Willebrand disease using 4 different platelet-dependent von Willebrand factor assays
- Open Access
- 11 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (13) , 4031-4040
Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2
Von Willebrand disease (VWD) type 2 is caused by qualitative abnormalities of von Willebrand factor (VWF). This study aimed to determine the genotypic and phenotypic characterizations of a large VWD type 2 cohort from Milan. We included 321 patients (54% female) within 148 unrelated families from 1995 to 2021. Patients were fully characterized using laboratory phenotypic tests, and the genotypic diagnosis was confirmed by target genetic analysis using Sanger sequencing. Patients were diagnosed with type 2A (n = 98; 48 families), 2B (n = 85; 38 families), 2M (n = 112; 50 families), or 2N (n = 26; 12 families). Eighty-two unique VWF variants, including 8 novel variants, were found. The potential pathogenic effect of novel variants was assessed by in silico analysis. Most patients were heterozygous for a single variant (n = 259; 81%), whereas 37 cases (11%) had 2 variants (4 homozygous, 9 in trans, and 24 in cis). Twenty-five patients (8%) had ≥3 variants, mainly as a result of gene conversions. Among the 82 distinct variants identified, 5 different types, including missense (n = 64), gene conversion (n = 10), synonymous (n = 1), deletion (n = 4), and splice (n = 3), were observed. The results from this large cohort showed that VWD type 2 is invariably due to variants that do not prevent the synthesis of the protein, and a vast majority of patients (88%) had missense variants. Given the complexity of type 2 diagnosis and the necessity of performing several phenotypic tests, genetic analysis for patients suspected of having type 2 is beneficial to establish the correct diagnosis.
- 11 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (13) , 4031-4040
Open AccessPhenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2
Von Willebrand disease (VWD) type 2 is caused by qualitative abnormalities of von Willebrand factor (VWF). This study aimed to determine the genotypic and phenotypic characterizations of a large VWD type 2 cohort from Milan. We included 321 patients (54% female) within 148 unrelated families from 1995 to 2021. Patients were fully characterized using laboratory phenotypic tests, and the genotypic diagnosis was confirmed by target genetic analysis using Sanger sequencing. Patients were diagnosed with type 2A (n = 98; 48 families), 2B (n = 85; 38 families), 2M (n = 112; 50 families), or 2N (n = 26; 12 families). Eighty-two unique VWF variants, including 8 novel variants, were found. The potential pathogenic effect of novel variants was assessed by in silico analysis. Most patients were heterozygous for a single variant (n = 259; 81%), whereas 37 cases (11%) had 2 variants (4 homozygous, 9 in trans, and 24 in cis). Twenty-five patients (8%) had ≥3 variants, mainly as a result of gene conversions. Among the 82 distinct variants identified, 5 different types, including missense (n = 64), gene conversion (n = 10), synonymous (n = 1), deletion (n = 4), and splice (n = 3), were observed. The results from this large cohort showed that VWD type 2 is invariably due to variants that do not prevent the synthesis of the protein, and a vast majority of patients (88%) had missense variants. Given the complexity of type 2 diagnosis and the necessity of performing several phenotypic tests, genetic analysis for patients suspected of having type 2 is beneficial to establish the correct diagnosis.
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 4247
Which Level of Emicizumab Is Necessary for a Good Hemostasis?
IntroductionEmicizumab is a recombinant, humanized, bispecific antibody restoring the function of missing activated factor VIII (FVIII) by bridging ac
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 4247
Open AccessWhich Level of Emicizumab Is Necessary for a Good Hemostasis?
IntroductionEmicizumab is a recombinant, humanized, bispecific antibody restoring the function of missing activated factor VIII (FVIII) by bridging ac
- 1 January 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (1) , 96-106
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease
- 1 January 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (1) , 96-106
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease
- 3 September 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (10) , 1125-1133
How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease
Gastrointestinal (GI) bleeding is distinctive of severe von Willebrand disease (VWD), generally arising in older patients; in most cases, blood transfusion and hospitalization are required. The presence of arteriovenous malformations is often described when endoscopic examinations are performed. Patients with congenital type 3, 2A, and 2B are those most frequently affected by this symptom, possibly due to the loss of high-molecular-weight multimers of von Willebrand factor (VWF). GI bleeding can also occur in patients affected by acquired von Willebrand syndrome. Endoscopic examination of the GI tract is necessary to exclude ulcers and polyps or cancer as possible causes of GI bleeding. In congenital VWD, prophylaxis with VWF/factor VIII concentrates is generally started after GI-bleeding events, but this therapy is not always successful. Iron supplementation must be prescribed to avoid chronic iron deficiency. Possible rescue therapies (high-dose statins, octreotide, thalidomide, lenalidomide, and tamoxifen) were described in a few case reports and series; however, surgery may be necessary in emergency situations or if medical treatment fails to stop bleeding. In this article, we present several clinical cases that highlight the clinical challenges of these patients and possible strategies for their long-term management.
- 3 September 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (10) , 1125-1133
How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease
Gastrointestinal (GI) bleeding is distinctive of severe von Willebrand disease (VWD), generally arising in older patients; in most cases, blood transfusion and hospitalization are required. The presence of arteriovenous malformations is often described when endoscopic examinations are performed. Patients with congenital type 3, 2A, and 2B are those most frequently affected by this symptom, possibly due to the loss of high-molecular-weight multimers of von Willebrand factor (VWF). GI bleeding can also occur in patients affected by acquired von Willebrand syndrome. Endoscopic examination of the GI tract is necessary to exclude ulcers and polyps or cancer as possible causes of GI bleeding. In congenital VWD, prophylaxis with VWF/factor VIII concentrates is generally started after GI-bleeding events, but this therapy is not always successful. Iron supplementation must be prescribed to avoid chronic iron deficiency. Possible rescue therapies (high-dose statins, octreotide, thalidomide, lenalidomide, and tamoxifen) were described in a few case reports and series; however, surgery may be necessary in emergency situations or if medical treatment fails to stop bleeding. In this article, we present several clinical cases that highlight the clinical challenges of these patients and possible strategies for their long-term management.
- 6 November 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (2) , E68-E70
Global coagulation tests to assess the value of the presurgical treatment in a patient with congenital factor XI deficiency and inhibitor
- 6 November 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (2) , E68-E70
Global coagulation tests to assess the value of the presurgical treatment in a patient with congenital factor XI deficiency and inhibitor